Gallbladder disorder
MONDO:0005281A disease involving the gall bladder.
Also known as: Gall bladder disorder, disease of gall bladder, disease or disorder of gall bladder, disorder of gall bladder, gall bladder disease, gall bladder disease or disorder, gallbladder disorder
219 clinical trials for this condition and its sub-types, 26 tagged with Gallbladder disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Gallbladder disorder
-
Gallbladder neoplasm 63 trials · 117 incl. sub-types
6 sub-types
- Gallbladder cancer 73 trials · 106 incl. sub-types Sub-types →
- Gallbladder biliary intraepithelial neoplasia 1 trial
- Benign neoplasm of gallbladder 0 trials Sub-types →
- Gallbladder adenoma 0 trials
- Gallbladder neuroendocrine neoplasm 0 trials Sub-types →
- Gallbladder papillary neoplasm 0 trials Sub-types →
-
Cholecystitis 35 trials · 65 incl. sub-types
4 sub-types
- Acute cholecystitis 35 trials
- Acalculous cholecystitis 0 trials
- Emphysematous cholecystitis 0 trials
- Xanthogranulomatous cholecystitis 0 trials
-
Cholecystolithiasis 14 trials
-
Biliary dyskinesia 12 trials
-
Polyp of gallbladder 8 trials
1 sub-type
- Gallbladder adenoma 0 trials
-
Hydrops of gallbladder 1 trial
-
Hereditary gallbladder disorder 0 trials · 1 incl. sub-types
3 sub-types
- Gallbladder disease 1 1 trial
- Gallbladder disease 2 0 trials
- Gallbladder disease 3 0 trials
-
Cholesterolosis of gallbladder 0 trials
-
Gallbladder duplication 0 trials
-
Occlusion of gallbladder 0 trials
Most studied deeper sub-types
-
New drug combo tested for tough bile duct cancers
Disease control Stopped earlyThis study tested a new drug called LSTA1 added to standard treatment for people with advanced bile duct or gallbladder cancer. The goal was to see if the combination is safe and works better than standard treatment alone. The trial was stopped early, and results are not yet avai…
Phase 2 • Sponsor: Lisata Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New cancer drug trial halted early – what we know
Disease control Stopped earlyThis study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental combo shows promise for tough bile duct cancer
Disease control Stopped earlyThis study tested whether adding an experimental drug called CPI-613 (devimistat) to standard chemotherapy (gemcitabine plus cisplatin) could help people with advanced biliary tract cancer that cannot be removed by surgery. The trial had two parts: first, finding the safest dose …
Phase 1/2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Experimental liver cancer drug shows promise in early trial
Disease control Stopped earlyThis phase 2 trial tested a drug called Taxoprexin (DHA-paclitaxel) in 13 people with advanced liver cancer that had not responded to prior treatments. The goal was to see if the drug could shrink tumors and how safe it was. The study was terminated early, so results are limited.
Phase 2 • Sponsor: American Regent, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Cancer gene hunt: could tumor maps guide better GI cancer treatment?
Knowledge-focused Stopped earlyThis study looked at genetic mutations in tumors from 565 people with advanced gastrointestinal cancers, including liver, bile duct, gallbladder, pancreas, esophagus, and stomach cancers. The goal was to see how often these mutations could be targeted by existing drugs and to tra…
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC